Ann Arbor, Michigan USA (January 29, 2004) – NanoBio® Corporation announced that the University of Michigan has been awarded patent # 6,506,803, “Method of Preventing and Treating Microbial Infections.”  Patents # 6,559,189 and 6,635,676, both entitled “Non-toxic Antimicrobial Compositions and Methods of Use,” have also been granted.  These patents, related international patents, and other University nanoemulsion inventions and patent applications, are licensed to NanoBio® Corporation on an exclusive, worldwide basis.  The new patents relate to composition and methods of use for NanoBio's antimicrobial technology and represent a non-toxic method of killing bacteria, fungus and virus.  

Dr. James R. Baker, Jr., CEO & CSO of NanoBio® stated that, “This intellectual property expands and complements our earlier patents and substantially improves our control over this technology and its field of use.  This will allow the commercialization on an extensive array of applications based on the NanoStat™ nanoemulsion technology platform.”

NanoBio® has several pharmaceutical treatments for fungal, viral and bacterial infections of the skin and mucous membranes in development based on University of Michigan's nanoemulsion technology.   The first topical product, a treatment for cold sores (Herpes labialis) plans to begin Phase II clinical trials in March 2004.  Clinical trials for a topical nail fungus (onychomycosis) treatment are scheduled to begin later this summer.

Additional longer-term products in development include treatments for genital herpes, shingles, and a broad-spectrum vaginal infection treatment that is efficacious against fungal, bacterial and parasitic infections.   NanoBio â products have an advantage over currently available treatments because they can be used topically, they do not cause toxicity or drug resistance and they kill multiple types of organisms.  

Company Background: NanoBio® Corporation is a Michigan “C” corporation that was formed in 2000 to commercialize nanoemulsion therapeutics based on its patented NanoStat TM antimicrobial nanoemulsion technology.  NanoBio® has advanced its pharmaceuticals using $7.5 million obtained from investors, a Michigan Life Science Corridor (MLSC) grant, and a grant from the United States Department of Defense.  

Dr. Baker and his colleagues at the Center for Biological Nanotechnology at the University of Michigan created the antimicrobial nanoemulsion technology with funding from the U.S. Department of Defense and NIH.  The technology was then exclusively licensed to NanoBio® for its commercial development and support. NanoBio® owns a comprehensive portfolio of intellectual property rights that include patents, proprietary formulations and processes, confidential data, and trademarks, which gives it a strong competitive advantage in introducing novel and efficacious antimicrobial products.